cDC1 are dispensable for in vivo cross-priming with IC. (A and B) In vitro proliferation of OT-I cultured with splenic cDC1 or cDC2 alone (0) or with 1 μg/ml of sOVA or OVA-IC (A) or with the indicated doses of sOVA or OVA-IC (B). Data shown are representative of two independent experiments. (B) Two-way ANOVA with Sidak’s multiple comparisons test, with a single pooled variance. *P < 0.05; ****P < 0.0001. (C) In vivo OT-I proliferation in WT, Δ32, and Δ1+2+3 mice on day 3 after intravenous immunization with 1 μg sOVA or 1 μg sOVA with anti-OVA antibody (OVA-IC). (D) Frequencies of OT-I proliferation from mice in C. Two-way ANOVA with Tukey’s multiple comparisons test. ns = not significant; ***P < 0.001; ****P < 0.0001. (E) In vitro proliferation of OT-I cultured with splenic cDC1 or cDC2 alone (0), 1 μg/ml of OVA-IC, 25,000 Abelson-mOVA, or 25,000 Abelson-mOVA preincubated with anti-OVA antibody. Unpaired t test. ns = not significant. (F) In vivo OT-I proliferation in WT, Δ32, and Δ1+2+3 mice on day 3 after intravenous immunization with 330,000 Abelson-mOVA preincubated anti-OVA antibody. (G) Frequencies of OT-I proliferation from mice in F. Two-way ANOVA with Tukey’s multiple comparisons test. ns = not significant; ***P < 0.001.